

ASX Announcement

Race Chief Financial Officer Appointment

18 March 2024 – Race Oncology Limited (“Race”) is pleased to announce the appointment of Mr Brendan Brown as Chief Financial Officer (CFO) of Race Oncology, effective from Monday 1 April 2024.

Brendan is a Partner and Director of Prime Accounting & Business Advisory Pty Ltd (“Prime”), part of the Prime Financial Group (ASX:PFG). He brings significant practical experience having worked with numerous life science clients through the past 20 years. Brendan is a Chartered Accountant (CA ANZ) and Registered Tax Agent with a Bachelor of Commerce (Accounting) from La Trobe University.

Brendan succeeds Ms Christina Manfre of PKF Sydney Pty Ltd. Race wishes to thank Christina for her contribution over the last two years.

Chief Executive Officer, Dr Daniel Tillett comments *“We thank Christina for her time with Race and welcome Brendan to his new role as Race CFO. Race has had a productive working relationship with Prime over the last two years being responsible for Race’s successful R&D Tax Incentive claims. We are pleased to be expanding our engagement with both Brendan and Prime as we advance our new formulation of bisantrene in the clinic in 2024.”*

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Race's lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a rich and unique clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin.

Race is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where we hope to deliver cardioprotection and enhanced anti-cancer activity in solid tumours. Race is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.

Race is investigating the effect of bisantrene on the m⁶A RNA pathway, following independent research published by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of the m⁶A RNA pathway has been described in numerous peer reviewed studies as a driver of a diverse range of cancers.

Race Oncology has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world.

Learn more at www.raceoncology.com.

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Daniel Tillett, CEO
info@raceoncology.com

Media contact:

Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au